Abstract
Patients' data were collected in the West China Hospital of Sichuan University Transcatheter Aortic Valve Replacement (WATCH TAVR) registration study (registered number: Characteristics Total (n = 444) Male (n = 243) Female (n = 201) P values Puncture 391 (88.06) 214 (88.07) 177 (88.06) 0.998 Predilation 181 (40.77) 94 (38.68) 87 (43.28) Post-dilation 22 (4.95) 12 (4.94) 10 (4.98) Contrast agent dose, mL 240 (230–330) 240 (220–300) 265 (230–330) Prothesis size, mm 26.0 (26.0–29.0) 26.5 (26.0–29.0) 26.0 (23.0–26.0) <0.001 Transcatheter approach 0.849 TFA 441 (99.32) 242 (99.59) 199 (99) TCA 2 (0.45) 0 2 (1) TSA 1 (0.23) 1 (0.41) 0 Prothesis type 0.066 CoreValve 40 (9.01) 25 (10.29) 15 (7.46) Venus A 245 (55.18) 141 (58.02) 104 (51.74) Venus–A Plus 23 (5.18) 11 (4.53) 12 (5.97) Lotus 29 (6.53) 13 (5.35) 16 (7.96) Vitaflow Ⅰ 28 (6.31) 14 (5.76) 14 (6.97) Vitaflow Ⅱ 2 (0.45) 1 (0.41) 1 (0.50) Edward S3 9 (2.03) 6 (2.47) 3 (1.49) Edward XT 18 (4.05) 7 (2.88) 11 (5.47) Taurasone 47 (10.59) 24 (9.88) 23 (11.44) Clinical outcomes Vascular complications 42 (9.46) 13 (5.35) 29 (14.43) 0.001 Major vascular complications 12 (2.70) 2 (0.82) 10 (4.98) Minor vascular complications 30 (6.76) 11 (4.53) 19 (9.45) Intra-TAVR bleeding 47 (10.63) 19 (7.88) 28 (13.93) 0.040 Minor bleeding 26 (5.88) 11 (4.56) 15 (7.46) Major bleeding 21 (4.75) 8 (3.32) 13 (6.47) Paravalvular leak 270 (60.81) 143 (58.85) 121 (63.18) 0.352 Mild PVL 165 (37.16) 85 (34.98) 80 (39.80) Moderate PVL 105 (23.65) 58 (23.87) 47 (23.38) Thrombotic event 21 (4.73) 10 (4.12) 11 (5.47) 0.502 Arrythmia 8 (1.80) 5 (2.06) 3 (1.49) 0.656 Stroke 8 (1.80) 4 (1.65) 4 (1.99) 0.786 PPI 80 (18.18) 46 (19.17) 34 (16.91) 0.557 New onset LBBB 127 (28.93) 73 (30.17) 54 (27.41) 0.527 Myocardial infarction 1 (0.23) 0 1 (0.50) 0.271 1-year death 35 (7.88) 20 (8.23) 15 (7.46) 0.765 1-to-3-year death 23 (5.18) 14 (5.76) 9 (4.48) 0.544 Over 3-year death 11 (2.48) 10 (4.12) 1 (0.50) 0.015 Data are presented as n (%) or median (interquartile range). [6,7] In the survival analysis, thirty-day mortality showed no statistical difference between the gender groups (Male vs. [...]this single-center study might not best represent the situations in other parts of China and in other Asian countries.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2 Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
3 Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
4 Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China